Total Valuation
Corcept Therapeutics has a market cap or net worth of CHF9.87B. The enterprise value is CHF9.99K.
Market CapCHF9.87B
Enterprise ValueCHF9.99K
Share Statistics
Corcept Therapeutics has 108,098,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108,098,400
Owned by Insiders10.79%
Owned by Institutions4.56%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)6.67%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.04M
Profits Per Employee134.48K
Employee Count730
Asset Turnover0.91
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 212.5. Corcept Therapeutics’s PEG ratio is -1.24.
PE Ratio212.5
PS Ratio4.75
PB Ratio5.58
Price to Fair Value5.58
Price to FCF25.49
Price to Operating Cash Flow106.16
PEG Ratio-1.24
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.
Revenue761.41M
Gross Profit748.43M
Operating Income44.80M
Pretax Income66.46M
Net Income99.65M
EBITDA68.35M
Earnings Per Share (EPS)0.95
Cash Flow
In the last 12 months, operating cash flow was 109.70M and capital expenditures -2.78M, giving a free cash flow of 106.92M billion.
Operating Cash Flow109.70M
Free Cash Flow106.92M
Free Cash Flow per Share0.99
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Corcept Therapeutics upcoming earnings date is Nov 4, 2026, TBA (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateNov 4, 2026
Ex-Dividend Date―
Financial Position
Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 1.33%
Current Ratio2.92
Quick Ratio2.85
Debt to Market Cap<0.01
Net Debt to EBITDA-1.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.
Income Tax-33.19M
Effective Tax Rate-0.50
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 51.20, with an EV/FCF ratio of 24.69.
EV to Sales4.60
EV to EBITDA51.20
EV to Free Cash Flow24.69
EV to Operating Cash Flow24.65
Balance Sheet
Corcept Therapeutics has CHF308.20M in cash and marketable securities with CHF9.42M in debt, giving a net cash position of CHF298.78M billion.
Cash & Marketable SecuritiesCHF308.20M
Total DebtCHF9.42M
Net CashCHF298.78M
Net Cash Per ShareCHF2.76
Tangible Book Value Per ShareCHF6.24
Margins
Gross margin is 98.30%, with operating margin of 5.88%, and net profit margin of 13.09%.
Gross Margin98.30%
Operating Margin5.88%
Pretax Margin8.73%
Net Profit Margin13.09%
EBITDA Margin8.98%
EBIT Margin8.73%
Analyst Forecast
The average price target for Corcept Therapeutics is CHF110.04, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF110.04
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast16.02%
EPS Growth Forecast-59.24%